ROIV
Roivant Sciences Ltd.$29.99
Live · FMPMay 29, 2026
Market cap
$21.57B
52w range
10.71 – 32.79
P / E
—
EPS
—
Volume
7.73M
Revenue · FY
—
Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
—
vs spot
n/a
Spot price
$29.99
Mkt cap $21.57B
subtle cardAnalyst PT consensus
$37.17
+23.94% vs spot
subtle cardMethods covered
0 / 0
0 in blend
subtle cardFootball field — ROIV
No methods produced a fair-value point estimate. Coverage may be limited for this symbol.
Method comparison
ROIV · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.14)β | × 1.14 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 9.56% |
| Pre-tax cost of debtkd | 5.96% |
| Effective tax ratet | 0.0% |
| After-tax cost of debt | 5.96% |
| Equity weight$0.0B | 0.0% |
| Debt weight$0.0B | 0.0% |
| WACC | 9.56% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | — |
| Analyst forward EPS growthFMP | — |
| Historical 5y revenue CAGRFY | — |
| Historical 5y EPS CAGRFY | — |
| Sustainable g (ROE × retention)Δ | — |
| Blended near-term growth (g₀) | 7.00% |
| Terminal growth (gₗ) | 2.50% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2024-03-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $37.17
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.